GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Buchang Pharmaceuticals Co Ltd (SHSE:603858) » Definitions » Research & Development

Shandong Buchang Pharmaceuticals Co (SHSE:603858) Research & Development : ¥344 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Shandong Buchang Pharmaceuticals Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Shandong Buchang Pharmaceuticals Co's Research & Development for the three months ended in Mar. 2024 was ¥46 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was ¥344 Mil.


Shandong Buchang Pharmaceuticals Co Research & Development Historical Data

The historical data trend for Shandong Buchang Pharmaceuticals Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Buchang Pharmaceuticals Co Research & Development Chart

Shandong Buchang Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 505.36 533.42 408.60 284.12 335.08

Shandong Buchang Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.84 63.47 50.71 184.07 46.02

Shandong Buchang Pharmaceuticals Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥344 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Buchang Pharmaceuticals Co  (SHSE:603858) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Shandong Buchang Pharmaceuticals Co Research & Development Related Terms

Thank you for viewing the detailed overview of Shandong Buchang Pharmaceuticals Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Buchang Pharmaceuticals Co (SHSE:603858) Business Description

Traded in Other Exchanges
N/A
Address
No. 369, Zhonghua West Road, Shandong Province, Heze, CHN, 274000
Shandong Buchang Pharmaceuticals Co Ltd is a pharmaceuticals company engaged in drug manufacturing. It specializes in the research and development, production and sale of Traditional Chinese patent medicines, supplemented by fields such as hi-tech industry and health industry. The company offers drugs for cardiac and cerebral vascular disease, diabetes, urinary and digestive disease, respiratory disease, gynecological disease and others. Geographically, the company holds its production bases in Shandong, Shaanxi, Hebei and Northeast China, with its marketing network spreading all over the major provinces of China.

Shandong Buchang Pharmaceuticals Co (SHSE:603858) Headlines

No Headlines